Affordable Access

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Authors
  • Bertheau, Philippe
  • Turpin, Elisabeth
  • Rickman, David S
  • Espié, Marc
  • de Reyniès, Aurélien
  • Feugeas, Jean-Paul
  • Plassa, Louis-François
  • Soliman, Hany
  • Varna, Mariana
  • de Roquancourt, Anne
  • Lehmann-Che, Jacqueline
  • Beuzard, Yves
  • Marty, Michel
  • Misset, Jean-Louis
  • Janin, Anne
  • de Thé, Hugues
Type
Published Article
Journal
PLoS Medicine
Publisher
Public Library of Science
Publication Date
Mar 01, 2007
Volume
4
Issue
3
Identifiers
PMID: 17388661
Source
Medline
License
Unknown

Abstract

This study demonstrates that, in noninflammatory breast cancers, TP53 status is a key predictive factor for response to this dose-dense epirubicin-cyclophosphamide regimen and further suggests that the basal subtype is exquisitely sensitive to this association. Given the well-established predictive value of complete responses for long-term survival and the poor prognosis of basal and TP53-mutant tumors treated with other regimens, this chemotherapy could be particularly suited for breast cancer patients with a mutant TP53, particularly those with basal features.

Report this publication

Statistics

Seen <100 times